TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34270445

Group type: EXPERIMENTAL
Intervention: Standardised and internationally validated psychiatric assessments (Diagnosis Infant and Preschool Assessment, Kiddie Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardised psychiatric assessments during five visits (baseline, 1 week after baseline, 1 month after baseline, 1 week after the end of the containment, and 1 month after the end of the containment)
Number of subjects: 0
Study: 34270522

Group type: EXPERIMENTAL
Intervention: Wearable sensor (Empatica E4)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Trained model on withheld data
Number of subjects: 46
Study: 34270700

Group type: EXPERIMENTAL
Intervention: Early RA (ESPOIR cohort)
Number of subjects: 1489

Group type: EXPERIMENTAL
Intervention: Early SpA (DESIR cohort)
Number of subjects: 1489

Group type: EXPERIMENTAL
Intervention: General findings for both diseases
Number of subjects: 1489
Study: 34270905

Group type: EXPERIMENTAL
Intervention: Bucindolol
Number of subjects: 0
Study: 34271077

Group type: EXPERIMENTAL
Intervention: School- and community-based intervention to promote healthy lifestyle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: School- and community-based intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: School- and community-based intervention for low-risk families
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: School- and community-based intervention for high-risk families
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incremental financial investments for high-risk families
Number of subjects: 0
Study: 34271131

Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM) at 33 °C
Number of subjects: 680

Group type: COMPARATOR
Intervention: Targeted temperature management (TTM) at 36 °C
Number of subjects: 680
Study: 34271173

Group type: EXPERIMENTAL
Intervention: Subcutaneous implantable cardioverter-defibrillator (S-ICD)
Number of subjects: 1254
Study: 34271312

Group type: EXPERIMENTAL
Intervention: IDH1-vac, a long IDH1R132H peptide vaccine
Number of subjects: 0
Study: 34271528

Group type: EXPERIMENTAL
Intervention: externally-paced deep breathing
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: self-paced deep breathing
Number of subjects: 25

Group type: COMPARATOR
Intervention: sitting quietly
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: self-paced Sheetali/Sheetkari pranayama
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: externally paced Sheetali/Sheetkari pranayama
Number of subjects: 25
Study: 34271913

Group type: EXPERIMENTAL
Intervention: MapSan intervention (shared sanitation facilities)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 0
Study: 34271922

Group type: EXPERIMENTAL
Intervention: Waist-worn devices (Actical, ActiGraph GT3X+, SW-200)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Thigh-worn devices (activPAL)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Ankle-worn devices (StepWatch)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Wrist-worn devices (ActiGraph GT3X+)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: All wearable technologies
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Speed and wear location
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 117
Study: 34272087

Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic therapies
Number of subjects: 0
Study: 34272204

Group type: EXPERIMENTAL
Intervention: Palliative systemic treatment (usual care arm of GAP 70+ Trial)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Increasing age by one year
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Receipt of ≥second line of chemotherapy
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Functional impairment
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Income ≤$50,000
Number of subjects: 369
Study: 34272304

Group type: EXPERIMENTAL
Intervention: Isatuximab (Isa)-lenalidomide (Len)-dexamethasone (Dex)
Number of subjects: 57
Study: 34272425

Group type: EXPERIMENTAL
Intervention: Esophageal Doppler monitoring (EDM) during postural change from steep Trendelenburg to supine position (T-off)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Esophageal Doppler monitoring (EDM)
Number of subjects: 125
Study: 34272471

Group type: EXPERIMENTAL
Intervention: Noninvasive neuromodulation (including ECT, rTMS, tDCS) targeting the prefrontal cortex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noninvasive neuromodulation
Number of subjects: 0
Study: 34272724

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Treatment withdrawal after 180 days
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 237
Study: 34272797

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 35
Study: 34273485

Group type: EXPERIMENTAL
Intervention: Biologic treatment
Number of subjects: 1884

Group type: COMPARATOR
Intervention: Maintenance systemic corticosteroids or uncontrolled by high-dosage inhaled corticosteroids
Number of subjects: 1884
Study: 34273526

Group type: EXPERIMENTAL
Intervention: Transplant ePROM (TXP) administered via mobile application
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Transplant ePROM (TXP)
Number of subjects: 232
Study: 34273558

Group type: EXPERIMENTAL
Intervention: Submaximal handgrip exercise test (6MHGT)
Number of subjects: 29
Study: 34273904

Group type: EXPERIMENTAL
Intervention: Secukinumab treatment for 52 weeks
Number of subjects: 0
Study: 34273963

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF) group
Number of subjects: 16533

Group type: COMPARATOR
Intervention: Non-AF group
Number of subjects: 16533
Study: 34274071

Group type: EXPERIMENTAL
Intervention: Integrated Care for Older People (ICOPE) Step 1 screening tool
Number of subjects: 759
Study: 34274072

Group type: EXPERIMENTAL
Intervention: History of hysterectomy
Number of subjects: 50286

Group type: EXPERIMENTAL
Intervention: History of endometriosis
Number of subjects: 50286
Study: 34274251

Group type: EXPERIMENTAL
Intervention: Exertional-desaturators during CPET
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Exertional-desaturators during low/moderate-intensity exercise
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Non-exertional-desaturators during high-intensity exercise
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cerebral-NIRS indices
Number of subjects: 24
Study: 34274293

Group type: EXPERIMENTAL
Intervention: Anticoagulation after transcatheter aortic valve replacement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 34274393

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) with sequential S-1
Number of subjects: 63
Study: 34274536

Group type: EXPERIMENTAL
Intervention: CD5-targeting fully human heavy-chain variable (FHV) CAR-T therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard CAR-T therapy (implied control)
Number of subjects: 0
Study: 34275061

Group type: EXPERIMENTAL
Intervention: Double dose proton pump inhibitor (PPI) therapy for 4 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: External upper esophageal sphincter (UES) compression device (Reflux Band) nightly along with PPI for 4 weeks
Number of subjects: 31
Study: 34275122

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 1568

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 1568

Group type: EXPERIMENTAL
Intervention: Baricitinib 1 mg
Number of subjects: 1568

Group type: COMPARATOR
Intervention: Skin Pain NRS responders
Number of subjects: 1568
Study: 34275336

Group type: EXPERIMENTAL
Intervention: Measurements of serum drug concentrations
Number of subjects: 0
Study: 34275403

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin 1.8 mg/kg by intravenous infusion on Day 1 of 3-week cycles (maximum 16 cycles)
Number of subjects: 0
Study: 34275469

Group type: EXPERIMENTAL
Intervention: Combination of breathing rate with Fourier coefficients, signal amplitude, and/or ARIMA coefficients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breathing rate alone
Number of subjects: 0
Study: 34275766

Group type: EXPERIMENTAL
Intervention: PatientsLikeMe (PLM) online patient health community
Number of subjects: 45
Study: 34275869

Group type: EXPERIMENTAL
Intervention: Community-led HIV self-testing (HIVST) intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Community-led HIVST
Number of subjects: 30
Study: 34276042

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies (in general)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeting IL-6 and IL-6R
Number of subjects: 0
Study: 34276329

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Stretching/Toning
Number of subjects: 74
Study: 34276537

Group type: EXPERIMENTAL
Intervention: Dopamine Receptor D1
Number of subjects: 0
Study: 34276547

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34277060

Group type: EXPERIMENTAL
Intervention: Impulse oscillometry measurements
Number of subjects: 567
Study: 34277393

Group type: EXPERIMENTAL
Intervention: Neoadjuvant Endocrine Therapy (NET) with gonadotropin-releasing hormone agonist and tamoxifen
Number of subjects: 187

Group type: COMPARATOR
Intervention: Neoadjuvant Chemotherapy (NCT) with adriamycin plus cyclophosphamide followed by taxane
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Neoadjuvant Endocrine Therapy (NET)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Neoadjuvant Chemotherapy (NCT)
Number of subjects: 187
Study: 34277437

Group type: EXPERIMENTAL
Intervention: Cryopreservation of ovarian tissue before HSCT
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cryopreservation of oocytes before HSCT
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cryopreservation of ovarian tissue after HSCT
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cryopreservation of oocytes after HSCT
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Hormone measurements post HSCT (FSH and AMH)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Overall survival until January 2021
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Reproductive outcomes post HSCT
Number of subjects: 39
Study: 34277679

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34277687

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34278044

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (750 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 34278053

Group type: EXPERIMENTAL
Intervention: Stereotactic radiation therapy (30 Gy in 5 fractions) for patients with 24 and 30 lesions.
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Stereotactic radiation therapy (12 Gy in 2 fractions) for the patient with 50 targets.
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Stereotactic radiation therapy treatment plans using volumetric modulated arc therapy.
Number of subjects: 5
Study: 34278100

Group type: EXPERIMENTAL
Intervention: Dyed sucralfate gel
Number of subjects: 19
Study: 34278169

Group type: EXPERIMENTAL
Intervention: selonsertib, firsocostat, or cilofexor, alone or in two-drug combinations
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study: 34278595

Group type: EXPERIMENTAL
Intervention: High-risk HLA genotype (DQ2.5/2.5 or DQ2.5/2.2)
Number of subjects: 2943

Group type: EXPERIMENTAL
Intervention: Age <18 years at diagnosis in index patients
Number of subjects: 2943

Group type: EXPERIMENTAL
Intervention: Age 41-60 years in relatives
Number of subjects: 2943

Group type: EXPERIMENTAL
Intervention: Being a sibling of the index patient
Number of subjects: 2943
Study: 34278973

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34279212

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34279239

Group type: EXPERIMENTAL
Intervention: Future Patient Telerehabilitation Program B
Number of subjects: 0

Group type: COMPARATOR
Intervention: Future Patient Telerehabilitation Program A
Number of subjects: 0
Study: 34279241

Group type: EXPERIMENTAL
Intervention: 12-week remote group-mediated physical activity and dietary weight loss intervention followed by a 12-week maintenance period
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control condition (self-monitoring tools only)
Number of subjects: 30
Study: 34279677

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 230
Study: 34279812

Group type: EXPERIMENTAL
Intervention: Cardiac MRI assessment
Number of subjects: 0
Study: 34280258

Group type: EXPERIMENTAL
Intervention: Ibrutinib (BTK inhibitor)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Asparaginase (ASNase) therapy
Number of subjects: 90
Study: 34280257

Group type: EXPERIMENTAL
Intervention: WT1-TCB antibody
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: WT1-TCB combined with lenalidomide
Number of subjects: 26
Study: 34280383

Group type: EXPERIMENTAL
Intervention: Worsened depressive symptoms
Number of subjects: 8784

Group type: COMPARATOR
Intervention: Stable depressive symptoms
Number of subjects: 8784

Group type: COMPARATOR
Intervention: Improved depressive symptoms
Number of subjects: 8784

Group type: EXPERIMENTAL
Intervention: Worsened depressive symptoms (after controlling for confounders)
Number of subjects: 8784
Study: 34280572

Group type: EXPERIMENTAL
Intervention: Pediatric Pain Screening Tool (PPST)
Number of subjects: 109
Study: 34280868

Group type: EXPERIMENTAL
Intervention: Breath analysis using SESI-HRMS
Number of subjects: 149
Study: 34281363

Group type: EXPERIMENTAL
Intervention: Ticagrelor Monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ticagrelor with Aspirin
Number of subjects: 0
Study: 34281606

Group type: EXPERIMENTAL
Intervention: Impact of Event Scale Revised score ≥ 33
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Mental Component Scale score
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Physical Component Scale score
Number of subjects: 107
Study: 34281607

Group type: EXPERIMENTAL
Intervention: Electronic Health Record (EHR) searches
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Reviewing upcoming clinic schedules
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Contacting past trial participants
Number of subjects: 446

Group type: COMPARATOR
Intervention: Non-use of EHR for recruitment
Number of subjects: 446
Study: 34281614

Group type: EXPERIMENTAL
Intervention: Community-wide mass drug administration (MDA) for soil-transmitted helminths (STH)
Number of subjects: 3
Study: 34281806

Group type: EXPERIMENTAL
Intervention: Mifepristone dispensing training
Number of subjects: 72
Study: 34281912

Group type: EXPERIMENTAL
Intervention: GSK2636771 (200 mg) plus enzalutamide (160 mg)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: GSK2636771 (300 mg) plus enzalutamide (160 mg)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: GSK2636771 (400 mg) plus enzalutamide (160 mg)
Number of subjects: 37
Study: 34282038

Group type: EXPERIMENTAL
Intervention: FRED flow diverter
Number of subjects: 145
Study: 34282069

Group type: EXPERIMENTAL
Intervention: Foveal sparing (FS) eyes
Number of subjects: 33

Group type: COMPARATOR
Intervention: Non-foveal sparing (non-FS) eyes
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Best-corrected distance visual acuity
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Macular pigment optical density measurements
Number of subjects: 33
Study: 34282079

Group type: EXPERIMENTAL
Intervention: Outpatient motivational enhancement therapy (4 sessions)
Number of subjects: 544

Group type: COMPARATOR
Intervention: Outpatient motivational enhancement therapy followed by community reinforcement approach for seniors (8 sessions)
Number of subjects: 544
Study: 34282128

Group type: EXPERIMENTAL
Intervention: Musculoskeletal Pain Survey shoulder subscale
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Tampa Kinesiophobia Scale-11
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Pain Catastrophizing Scale
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Fear of Pain Questionnaire
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Chronic Pain Coping Inventory-42
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Subjective Quality of Life Questionnaire
Number of subjects: 35
Study: 34282296

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34282409

Group type: EXPERIMENTAL
Intervention: Tracheostomy
Number of subjects: 1605
Study: 34282496

Group type: EXPERIMENTAL
Intervention: Deceased donor liver-derived natural killer (NK) cell infusion
Number of subjects: 18
Study: 34282506

Group type: EXPERIMENTAL
Intervention: Biosynthetic mesh (Phasix™)
Number of subjects: 84
Study: 34282539

Group type: EXPERIMENTAL
Intervention: Real-time diagnostic tool using time-frequency analysis (TFA) of log files
Number of subjects: 173
Study: 34282579

Group type: EXPERIMENTAL
Intervention: MAGUS device for endoscopic septotomy
Number of subjects: 2
Study: 34282646

Group type: EXPERIMENTAL
Intervention: rGV (R package for glycemic variability metrics)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High glucose
Number of subjects: 0
Study: 34282853

Group type: EXPERIMENTAL
Intervention: Exercise training (various programs)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Resistance exercise training (squats using a vibration platform)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Supervised upper limb exercise (SULP)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Multimodal exercise training
Number of subjects: 438

Group type: COMPARATOR
Intervention: Multimodal exercise programs (7 weeks vs 14 weeks)
Number of subjects: 438
Study: 34283023

Group type: EXPERIMENTAL
Intervention: Tablet intervention containing IPV questions and a film to promote safety behaviors
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 10
Study: 34283027

Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment and intervention (EMAI)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control arm (EMA data submission only)
Number of subjects: 48
Study: 34283029

Group type: EXPERIMENTAL
Intervention: Detection of urinary exosomal CA9 using transmission electron microscopy, flow cytometry, and reverse transcription-quantitative polymerase chain reaction.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Noncancer patients (control group) for comparison.
Number of subjects: 100
Study: 34283213

Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV)
Number of subjects: 7413
Study: 34283294

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT-AFL) treat-and-extend (T&E) regimen
Number of subjects: 246
Study: 34283629

Group type: EXPERIMENTAL
Intervention: Allogeneic stem-cell transplantation (HSCT) after 5-aza pretreatment
Number of subjects: 190

Group type: COMPARATOR
Intervention: Continuous 5-aza treatment
Number of subjects: 190
Study: 34283704

Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newborn screening
Number of subjects: 0
Study: 34284523

Group type: EXPERIMENTAL
Intervention: NF-κB decoy injection into degenerated IVDs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NF-κB decoy injection
Number of subjects: 0
Study: 34284599

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) performed in 175 patients (51.6%); mechanical thrombectomy in 139 patients.
Number of subjects: 339

Group type: COMPARATOR
Intervention: Medical management (control group).
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (EVT) group.
Number of subjects: 339
Study: 34285010

Group type: EXPERIMENTAL
Intervention: Smartphone application for data collection including personal profile, monthly event tracker, and patient-reported outcomes instruments.
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: EQ-5D-5L
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Myasthenia Gravis Activities of Daily Living
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Myasthenia Gravis Quality of Life 15-item revised scale
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Health Utilities Index III
Number of subjects: 2000
Study: 34285097

Group type: EXPERIMENTAL
Intervention: Lower LDL and statin use
Number of subjects: 5047

Group type: EXPERIMENTAL
Intervention: SBP levels 120-139 mmHg and DBP levels 80-89 mmHg
Number of subjects: 5047

Group type: COMPARATOR
Intervention: Lower blood pressure levels
Number of subjects: 5047
Study: 34285574

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 1699

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1699
Study: 34285598

Group type: EXPERIMENTAL
Intervention: Trazpiroben 25 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Itraconazole 200 mg once daily (days 1-5) + Trazpiroben 25 mg post itraconazole on day 4
Number of subjects: 12
Study: 34286103

Group type: EXPERIMENTAL
Intervention: Increased dose rifampicin and adjunctive linezolid, with or without aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34286354

Group type: EXPERIMENTAL
Intervention: Best possible medication history (BPMH) by hospital pharmacist at inclusion and therapeutic drug monitoring
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pharmacist interventions
Number of subjects: 51
Study: 34286454

Group type: EXPERIMENTAL
Intervention: Insulin glargine 100 U/mL (Gla-100) starting dose of 0.3 U/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla-100) starting dose of 0.2 U/kg
Number of subjects: 0
Study: 34286459

Group type: EXPERIMENTAL
Intervention: VP-102 topical application once every 14 days (Cohort 1)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: VP-102 topical application once every 21 days in conjunction with paring (Cohort 2)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Safety assessments for both cohorts
Number of subjects: 56